Teva Pharmaceutical (NYSE: TEVA) insider to sell 91,345 shares via Citigroup

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited reported a proposed sale of 91,345 ordinary shares through Citigroup Global Markets Inc. with an apparent aggregate value of $2,983,515.95, dated 03/04/2026. The filing lists recent dispositions by Daniell Richard of 115,468 shares on 12/09/2025 for $3,311,131.04 and 128,985 shares on 03/03/2026 for $4,173,941.70.

Insights

Securities Compliance Attorney

Form 144 notifies a brokered sale of 91,345 shares and lists recent insider dispositions.

Form 144 is a seller notice for restricted or control securities; the entry shows 91,345 ordinary shares with Citigroup Global Markets Inc. and an aggregate amount of $2,983,515.95 dated 03/04/2026. This indicates a planned broker-assisted transaction under Rule 144 reporting procedures.

Recent completed sales by Daniell Richard are recorded as 115,468 shares (12/09/2025) for $3,311,131.04 and 128,985 shares (03/03/2026) for $4,173,941.70. Cash‑flow treatment and any holding-period or volume-limit qualifiers are not stated in the excerpt; subsequent filings or broker confirmations may provide settlement details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	91345	2983515.95	1149812898	03/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/04/2022	RESTRICTED SHARE AWARD	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			53973	03/04/2026	COMPENSATION
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			37372	03/04/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniell Richard TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	12/09/2025	115468	3311131.04
Daniell Richard TEVA PHARMACUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	128985	4173941.70

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Teva's Form 144 filing mean for shareholders?

It notifies the SEC of a proposed sale of 91,345 ordinary shares through a broker on 03/04/2026. The form is an administrative disclosure required for restricted or control securities before public resale.

Who is listed as the broker for the planned Teva sale?

The filing lists Citigroup Global Markets Inc. as the broker handling the proposed sale. The entry pairs the broker with the 91,345 ordinary shares and an aggregate amount of $2,983,515.95.

What recent insider sales by Daniell Richard are disclosed in the filing?

The excerpt shows sales of 115,468 shares on 12/09/2025 for $3,311,131.04 and 128,985 shares on 03/03/2026 for $4,173,941.70. These are reported past dispositions in the Form 144.

Does the Form 144 state who receives the sale proceeds?

The filing lists aggregate dollar amounts for the proposed and recent sales but does not state who will receive the proceeds. The document does not specify cash‑flow recipients in the provided excerpt.